Valoctocogene roxaparvovec gene transfer in participants with HIV.
作者信息
Ragni Margaret V, Majerus Elaine, Fong Sylvia, Yates Bridget, Scheeler Stephen, Razon Lisa, Yu Hua, Reddy Divya B, Robinson Tara M
机构信息
Medicine and Clinical and Translational Science, Department of Medicine, Division Hematology/Oncology, University of Pittsburgh Medical Center, Hemophilia Center of Western Pennsylvania, Pittsburgh, PA.
Department of Medicine, Washington University in St. Louis, St. Louis, MO.
出版信息
Blood Adv. 2023 Apr 25;7(8):1525-1530. doi: 10.1182/bloodadvances.2022008948.
Abstract
摘要
相似文献
1
Valoctocogene roxaparvovec gene transfer in participants with HIV.
Blood Adv. 2023 Apr 25;7(8):1525-1530. doi: 10.1182/bloodadvances.2022008948.
2
Valoctocogene Roxaparvovec: First Approval.
Drugs. 2022 Sep;82(14):1505-1510. doi: 10.1007/s40265-022-01788-y.
3
Assessing the potential cost-effectiveness of a gene therapy for the treatment of hemophilia A.
J Med Econ. 2020 May;23(5):501-512. doi: 10.1080/13696998.2020.1721508. Epub 2020 Feb 13.
4
Persistence of haemostatic response following gene therapy with valoctocogene roxaparvovec in severe haemophilia A.
Haemophilia. 2021 Nov;27(6):947-956. doi: 10.1111/hae.14391. Epub 2021 Aug 11.
5
Enhancement of retroviral transduction by cationic liposomes.
Methods Enzymol. 2003;373:493-506. doi: 10.1016/S0076-6879(03)73031-6.
6
Prednisolone Does Not Regulate Factor VIII Expression in Mice Receiving AAV5-hFVIII-SQ: Valoctocogene Roxaparvovec.
Mol Ther Methods Clin Dev. 2019 Nov 21;17:13-20. doi: 10.1016/j.omtm.2019.11.007. eCollection 2020 Jun 12.
7
Transitioning patients with severe haemophilia A from emicizumab prophylaxis to valoctocogene roxaparvovec gene therapy: Real-world clinical experience.
Haemophilia. 2024 Sep;30(5):1247-1249. doi: 10.1111/hae.15086. Epub 2024 Aug 13.
8
Intracellular antibodies against HIV-1 envelope protein for AIDS gene therapy.
Hum Gene Ther. 1998 Jul 20;9(11):1627-42. doi: 10.1089/hum.1998.9.11-1627.
9
Evaluation of one-stage and chromogenic assays for the laboratory measurement of factor VIII activity following valoctocogene roxaparvovec infusion.
Haemophilia. 2024 Sep;30(5):1221-1224. doi: 10.1111/hae.15064. Epub 2024 Jun 6.
10
Early Phase Clinical Immunogenicity of Valoctocogene Roxaparvovec, an AAV5-Mediated Gene Therapy for Hemophilia A.
Mol Ther. 2021 Feb 3;29(2):597-610. doi: 10.1016/j.ymthe.2020.12.008. Epub 2020 Dec 10.
引用本文的文献
1
Efficacy, safety, and quality of life 4 years after valoctocogene roxaparvovec gene transfer for severe hemophilia A in the phase 3 GENEr8-1 trial.
Res Pract Thromb Haemost. 2024 Oct 30;8(8):102615. doi: 10.1016/j.rpth.2024.102615. eCollection 2024 Nov.
2
UKHCDO gene therapy taskforce: Guidance for implementation of haemophilia gene therapy into routine clinical practice for adults.
Haemophilia. 2025 Jan;31(1):26-38. doi: 10.1111/hae.15125. Epub 2024 Nov 20.
3
Roctavian gene therapy for hemophilia A.
Blood Adv. 2024 Oct 8;8(19):5179-5189. doi: 10.1182/bloodadvances.2023011847.
4
Optimizing liver health before and after gene therapy for hemophilia A.
Blood Adv. 2024 Oct 8;8(19):5203-5212. doi: 10.1182/bloodadvances.2024013059.
5
Application of --cultured primary hepatocytes to evaluate species translatability and AAV transduction mechanisms of action.
Mol Ther Methods Clin Dev. 2022 May 29;26:61-71. doi: 10.1016/j.omtm.2022.05.008. eCollection 2022 Sep 8.
本文引用的文献
1
Vector genome loss and epigenetic modifications mediate decline in transgene expression of AAV5 vectors produced in mammalian and insect cells.
Mol Ther. 2022 Dec 7;30(12):3570-3586. doi: 10.1016/j.ymthe.2022.11.001. Epub 2022 Nov 7.
2
Application of --cultured primary hepatocytes to evaluate species translatability and AAV transduction mechanisms of action.
Mol Ther Methods Clin Dev. 2022 May 29;26:61-71. doi: 10.1016/j.omtm.2022.05.008. eCollection 2022 Sep 8.
3
Valoctocogene Roxaparvovec Gene Therapy for Hemophilia A.
N Engl J Med. 2022 Mar 17;386(11):1013-1025. doi: 10.1056/NEJMoa2113708.
4
Real-World Rates of Bleeding, Factor VIII Use, and Quality of Life in Individuals with Severe Haemophilia A Receiving Prophylaxis in a Prospective, Noninterventional Study.
J Clin Med. 2021 Dec 18;10(24):5959. doi: 10.3390/jcm10245959.
5
Multiyear Factor VIII Expression after AAV Gene Transfer for Hemophilia A.
N Engl J Med. 2021 Nov 18;385(21):1961-1973. doi: 10.1056/NEJMoa2104205.
6
Persistence of haemostatic response following gene therapy with valoctocogene roxaparvovec in severe haemophilia A.
Haemophilia. 2021 Nov;27(6):947-956. doi: 10.1111/hae.14391. Epub 2021 Aug 11.
7
NNRTI and Liver Damage: Evidence of Their Association and the Mechanisms Involved.
Cells. 2021 Jul 4;10(7):1687. doi: 10.3390/cells10071687.
8
Patients' and parents' satisfaction with, and preference for, haemophilia A treatments: a cross-sectional, multicentre, observational study.
Haemophilia. 2021 Jul;27(4):563-573. doi: 10.1111/hae.14304. Epub 2021 Jun 15.
9
Hepatotoxicity of Contemporary Antiretroviral Drugs: A Review and Evaluation of Published Clinical Data.
Cells. 2021 May 20;10(5):1263. doi: 10.3390/cells10051263.
10
Antiretroviral Drugs Regulate Epigenetic Modification of Cardiac Cells Through Modulation of H3K9 and H3K27 Acetylation.
Front Cardiovasc Med. 2021 Apr 9;8:634774. doi: 10.3389/fcvm.2021.634774. eCollection 2021.
Zotero 插件